Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone | Zendy

J Mira | Zendy; Luís F. LópezCortés | Zendy; Pablo Barreiro | Zendy; Cristina Tural | Zendy; M. Torres-Tortosa | Zendy; Ignacio de los Santos | Zendy; P. Martín-Rico | Zendy; Maria José Ríos-Villegas | Zendy; Juan José Hernandez-Burruezo | Zendy; Dolores Merino | Zendy; Miguel Ángel LópezRuz | Zendy; Antonio Rivero | Zendy; L. Munoz | Zendy; Mercedes GonzálezSerrano | Zendy; Antonio Collado | Zendy; Juan Macı́as | Zendy; Pompeyo Viciana | Zendy; Vincent Soriano | Zendy; Juan A. Pineda | Zendy

Open Access

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

Author(s) -

J Mira,

Luís F. LópezCortés,

Pablo Barreiro,

Cristina Tural,

M. Torres-Tortosa,

Ignacio de los Santos,

P. Martín-Rico,

Maria José Ríos-Villegas,

Juan José Hernandez-Burruezo,

Dolores Merino,

Miguel Ángel LópezRuz,

Antonio Rivero,

L. Munoz,

Mercedes GonzálezSerrano,

Antonio Collado,

Juan Macı́as,

Pompeyo Viciana,

Vincent Soriano,

Juan A. Pineda

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn420

Subject(s) - abacavir , lamivudine , emtricitabine , ribavirin , pegylated interferon , medicine , virology , reverse transcriptase inhibitor , gastroenterology , hepatitis c virus , viral load , hepatitis b virus , virus , antiretroviral therapy

To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of abacavir plus lamivudine with that observed in subjects who receive tenofovir plus lamivudine or emtricitabine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research